You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus
  1. Yasushi Kondo1,
  2. Yuko Kaneko1,
  3. Tatsuhiro Oshige1,
  4. Hiroyuki Fukui1,
  5. Shuntaro Saito1,
  6. Mikio Okayama2,
  7. Hirofumi Kamata3,
  8. Makoto Ishii3,
  9. Naoki Hasegawa4,
  10. Koichi Fukunaga3,
  11. Tsutomu Takeuchi1
  1. 1 Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
  2. 2 Division of Haematology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
  3. 3 Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
  4. 4 Department of Infectious Diseases, Center for Infection Diseases and Infection Control, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
  1. Correspondence to Dr Yasushi Kondo, Department of Rheumatology, Keio University School of Medicine, Tokyo 160-8582, Japan; yasutonko{at}a8.keio.jp

https://doi.org/10.1136/annrheumdis-2020-218157

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read the article regarding COVID-19 in patients with systemic lupus erythematosus (SLE) by Mathian et al 1 with great interest. We would like to report a case with SLE with COVID-19 who presented severe relapse of thrombocytopaenia. Mild thrombocytopaenia during COVID-19 is frequently observed, and immune thrombocytopaenia (ITP) has also been reported.2 3 Management of ITP during active COVID-19 can be difficult as immunosuppressive therapies can exacerbate infections, and the recovery of platelet count may lead to thrombosis due to coagulopathy caused in COVID-19.4 Here, we report a case with severe ITP relapse in patients with SLE during a course of COVID-19.

    A 58-year-old woman with a nearly 20-year history of SLE was admitted to our hospital with COVID-19. Her main manifestation of SLE was ITP, and her platelet count was low but stable at approximately 60×109/ L with 5 mg of prednisolone (PSL) since the …

    View Full Text

    Footnotes

    • Contributors YaK and YuK drafted the manuscript. TO, HF, SS, MO and HK were responsible for the clinical care of the patients. MI, NH, KF and TT supervised the conduct of researchers involved in the study and made critical revisions to the paper to enhance intellectual content. All authors read and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles